123 related articles for article (PubMed ID: 11854657)
21. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
Krafft A; Breymann C
J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
[TBL] [Abstract][Full Text] [Related]
22. Amniotic fluid volume responses to intra-amniotic infusion of lactate in fetal sheep.
Scheve EJ; Brace RA
J Soc Gynecol Investig; 2000; 7(2):96-101. PubMed ID: 10785608
[TBL] [Abstract][Full Text] [Related]
23. Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.
Chen L; Jiang H; Gao W; Tu Y; Zhou Y; Li X; Zhu Z; Jiang Q; Zhan H; Yu J; Fu C; Gao Y
BMJ Open; 2016 Oct; 6(10):e012231. PubMed ID: 27855097
[TBL] [Abstract][Full Text] [Related]
24. A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemia.
Veng-Pedersen P; Modi NB; Widness JA; Pereira LM; Schmidt RL; Georgieff MK
J Pharm Sci; 1993 Aug; 82(8):804-7. PubMed ID: 8377118
[TBL] [Abstract][Full Text] [Related]
25. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
Ohlsson A; Aher SM
Cochrane Database Syst Rev; 2006 Jul; (3):CD004863. PubMed ID: 16856062
[TBL] [Abstract][Full Text] [Related]
26. Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor.
Silberbach M; Woods LL; Hohimer AR; Shiota T; Matsuda Y; Davis LE
Pediatr Res; 1995 Nov; 38(5):722-8. PubMed ID: 8552440
[TBL] [Abstract][Full Text] [Related]
27. The effect of preoperative recombinant erythropoietin on postoperative hematocrit level after orthognathic surgery.
Politano N; Jaskolka M; Blakey G; Turvey T; White R; Phillips C
J Oral Maxillofac Surg; 2012 Nov; 70(11):e625-30. PubMed ID: 22939643
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy.
Breymann C; Visca E; Huch R; Huch A
Am J Obstet Gynecol; 2001 Mar; 184(4):662-7. PubMed ID: 11262469
[TBL] [Abstract][Full Text] [Related]
29. Fetal plasma erythropoietin concentration in red blood cell-isoimmunized pregnancies.
Thilaganathan B; Salvesen DR; Abbas A; Ireland RM; Nicolaides KH
Am J Obstet Gynecol; 1992 Nov; 167(5):1292-7. PubMed ID: 1442979
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin does not cross the placenta into the fetus.
Zanjani ED; Pixley JS; Slotnick N; MacKintosh FR; Ekhterae D; Clemons G
Pathobiology; 1993; 61(3-4):211-5. PubMed ID: 8216843
[TBL] [Abstract][Full Text] [Related]
31. Effective administration of erythropoietin for renal anemia.
Masunaga H; Ueda M; Sawai T; Kawanishi G
Nihon Juigaku Zasshi; 1989 Aug; 51(4):783-8. PubMed ID: 2585932
[TBL] [Abstract][Full Text] [Related]
32. Erythropoietin in the treatment of iron deficiency anemia during pregnancy.
Sifakis S; Angelakis E; Vardaki E; Koumantaki Y; Matalliotakis I; Koumantakis E
Gynecol Obstet Invest; 2001; 51(3):150-6. PubMed ID: 11306899
[TBL] [Abstract][Full Text] [Related]
33. The effect of haemorrhage on erythropoietin concentration in the mature ovine fetus.
Moritz KM; Cooper E; Wintour EM
J Dev Physiol; 1992 Mar; 17(3):157-61. PubMed ID: 1326576
[TBL] [Abstract][Full Text] [Related]
34. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity.
Haiden N; Klebermass K; Cardona F; Schwindt J; Berger A; Kohlhauser-Vollmuth C; Jilma B; Pollak A
Pediatrics; 2006 Jul; 118(1):180-8. PubMed ID: 16818564
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and economic repercussions of changing the erythropoietin administration route].
Rodríguez JR; Ruiz E; Vázquez G; Ruiz Cicero E
Nefrologia; 2005; 25(3):343-4. PubMed ID: 16053021
[No Abstract] [Full Text] [Related]
37. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
38. Swallowing, urine flow, and amniotic fluid volume responses to prolonged hypoxia in the ovine fetus.
Thurlow RW; Brace RA
Am J Obstet Gynecol; 2003 Aug; 189(2):601-8. PubMed ID: 14520242
[TBL] [Abstract][Full Text] [Related]
39. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
40. Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
Gardner DS; Fletcher AJ; Fowden AL; Giussani DA
Endocrinology; 2001 Feb; 142(2):589-98. PubMed ID: 11159829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
